Research programme: cancer therapeutics - Stainwei Biotech

Drug Profile

Research programme: cancer therapeutics - Stainwei Biotech

Alternative Names: hAB 21; M23; P16

Latest Information Update: 18 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Stainwei Biotech
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Placenta growth factor inhibitors; Programmed cell death-1 receptor antagonists; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 03 May 2017 hAB 21 is still in preclinical development for Cancer in China
  • 03 May 2017 Stainwei Biotech announces intention to submit IND for hAB 21 to the China FDA for Solid tumours (Late-stage disease) in the second half of 2017
  • 03 May 2017 Stainwei Biotech announces intention to submit IND for hAB 21 to the US FDA for Solid tumours (Late-stage disease) in the second half of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top